Cover Image

Redbiotec AG:產品平台分析

Redbiotec AG - Product Pipeline Review - 2014

出版商 Global Markets Direct 商品編碼 253778
出版日期 內容資訊 英文 17 Pages
Back to Top
Redbiotec AG:產品平台分析 Redbiotec AG - Product Pipeline Review - 2014
出版日期: 2014年12月10日 內容資訊: 英文 17 Pages



Redbiotec AG 是以各種病毒相關疾病為標的,致力於開發疫苗的生物製藥企業。該公司的開發中產品適用於先天性巨細胞病毒感染疾病和子宮頸癌症,流感等領域。該公司同時也致力於開發以皰疹病毒第四型(EB病毒)及水痘帶狀皰疹病毒為標的皰疹疫苗。

本報告提供Redbiotec AG 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Redbiotec AG的基本資料

  • Redbiotec AG概要
  • 主要資訊
  • 企業資料

Redbiotec AG:R&D概要

  • 主要的治療範圍

Redbiotec AG:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Redbiotec AG:藥物簡介

  • RBT-101
  • RBT-201
  • RBT-301

Redbiotec AG:開發平台分析

  • 各分子類型

Redbiotec AG:最近的開發平台趨勢

Redbiotec AG:暫停中的計劃

Redbiotec AG:總公司和子公司的所在地



Product Code: GMDHC06617CDB


Global Markets Direct's, 'Redbiotec AG - Product Pipeline Review - 2014', provides an overview of the Redbiotec AG's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Redbiotec AG's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


  • The report provides brief overview of Redbiotec AG including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Redbiotec AG's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Redbiotec AG's pipeline products

Reasons to buy

  • Evaluate Redbiotec AG's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Redbiotec AG in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Redbiotec AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Redbiotec AG and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Redbiotec AG
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Redbiotec AG and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Redbiotec AG Snapshot
    • Redbiotec AG Overview
    • Key Information
    • Key Facts
  • Redbiotec AG - Research and Development Overview
    • Key Therapeutic Areas
  • Redbiotec AG - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Redbiotec AG - Drug Profiles
    • RBT-101
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RBT-201
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RBT-301
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Redbiotec AG - Pipeline Analysis
    • Redbiotec AG - Pipeline Products by Molecule Type
  • Redbiotec AG - Recent Pipeline Updates
  • Redbiotec AG - Dormant Projects
  • Redbiotec AG - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Redbiotec AG, Key Information
  • Redbiotec AG, Key Facts
  • Redbiotec AG - Pipeline by Indication, 2014
  • Redbiotec AG - Pipeline by Stage of Development, 2014
  • Redbiotec AG - Monotherapy Products in Pipeline, 2014
  • Redbiotec AG - Pipeline by Molecule Type, 2014
  • Redbiotec AG - Recent Pipeline Updates, 2014
  • Redbiotec AG - Dormant Developmental Projects,2014

List of Figures

  • Redbiotec AG - Pipeline by Top 10 Indication, 2014
Back to Top